QIMING U.S. VENTURES MANAGEMENT, LLC
Follow13F filer, CIK 1909617, BELLEVUE, WA
QIMING U.S. VENTURES MANAGEMENT, LLC reported $23,615,986 across 6 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001415889-25-021900
- Period
- 2025-06-30
- Reported value
- $23.6M
- Holdings
- 6
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Holdings, Q2 2025
Share positions as resolved from 13F-HR 0001415889-25-021900, largest first. % of portfolio is the value over $23,615,986, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| Tourmaline Bio IncTourmaline Bio Inc | 741,691 | $11.9M | 50.22% | 0 | |||
| JSPRJASPER THERAPEUTICS INC | 928,964 | $5.16M | 21.83% | 0 | Timeline | ||
| KRROKORRO BIO INC | 368,085 | $4.6M | 19.47% | 0 | Timeline | ||
| VTYXVENTYX BIOSCIENCES INC | 412,225 | $882K | 3.74% | 0 | Timeline | ||
| HILLEVAX INCHILLEVAX INC | 372,615 | $742K | 3.14% | 0 | |||
| KZRKEZAR LIFE SCIENCES INC | 82,871 | $380K | 1.61% | 0 | Timeline |
How Q2 2025 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001415889-25-021900 | base | 2025-08-14 | acceptance time not in the bulk data set |